Dr Lal PathLabs Limited, a prominent diagnostic and healthcare service provider, has announced its financial results for the quarter ending March 31, 2026. The company reported a revenue of ₹703 crore, marking a 16.6% increase compared to the previous year.
The consolidated performance for Q4 FY26 highlights several key financial metrics. The company’s EBITDA rose by 10.5%, achieving a margin of 26.6%. Additionally, the profit after tax (PAT) for the quarter stood at ₹132 crore, with a margin of 18.8%.
Dr Lal PathLabs has also declared a final dividend of 40%, translating to ₹4 per share. As of March 31, 2026, the company reported cash and cash equivalents amounting to ₹1,526 crore.
The company continues to expand its footprint across India, operating 312 clinical laboratories, including major reference labs in Delhi, Kolkata, Bangalore, and Mumbai. It also manages 7,727 patient service centres and 13,935 pick-up points, catering to a diverse clientele comprising individual patients, hospitals, healthcare providers, and corporate customers.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).